antihemophilic factor

(redirected from Advate)
Also found in: Dictionary, Thesaurus, Medical.

antihemophilic factor

[¦an·tē‚hē·mə′fil·ik ‚fak·tər]
(biochemistry)
A soluble protein clotting factor in mammalian blood. Also known as factor VIII; thromboplastinogen.
References in periodicals archive ?
BAX 855 is a full-length longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] - the most widely chosen rFVIII in the world.
This Phase I study suggests that BAX 855 retains the underlying attributes of ADVATE and has the potential for less frequent dosing, creating a potential new option for hemophilia A patients.
These collaborations focus on further advancing ADVATE, with the objective of reducing the frequency of infusions and enhancing quality of life for hemophilia patients.
This launch follows the US Food and Drug Administration's (FDA) approval of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on full-length ADVATE [Antihemophilic Factor (Recombinant)].
7 billion, up 8%, driven primarily by double-digit growth and continued strong demand for hemophilia therapies (+11% to $942 million), including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] and FEIBA (an inhibitor therapy).
This was primarily the result of robust growth in demand for ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)], and other plasma-based therapeutics including FEIBA, an inhibitor bypass therapy, and products to treat hereditary emphysema.
Baxter International achieved positive results from its Phase III trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.
M2 EQUITYBITES-April 25, 2014-Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A
M2 PHARMA-April 25, 2014-Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A
Excluding the impact of foreign currency, BioScience sales rose 4 percent driven primarily by improved demand, particularly in the United States, for ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] for the treatment of hemophilia, and strong growth from select specialty plasma-based therapeutics and the company's portfolio of surgical sealants.
163/2006, for the award of the supply of the drug Advate for a period of 4 months.
The current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the company's recombinant factor VIII (rFVIII) for the treatment of patients with hemophilia A.